149(top 1%)
papers
4.9K(top 1%)
citations
34(top 1%)
h-index
68(top 1%)
g-index
152
all documents
5.2K
doc citations
947
citing journals

Top Articles

#TitleJournalYearCitations
1Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating MutationsCancer Research2008574
2Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOSAnnals of Oncology2018432
3Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsClinical Cancer Research2009255
4AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cellsNature Communications2019223
5Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studiesNature Medicine2020209
6Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese CohortJournal of Thoracic Oncology2011196
7PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1Proceedings of the National Academy of Sciences of the United States of America2013175
8EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC InhibitionCancer Research2013151
9Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung CancerCancer Discovery2016132
10Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2Nature Communications2015106
11Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer CellsClinical Cancer Research2012104
12Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung CancerClinical Cancer Research2011101
13Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung CancerClinical Cancer Research201093
14A Novel Targeting Therapy of Malignant Mesothelioma Using Anti-Podoplanin AntibodyJournal of Immunology201382
15Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung CancerMolecular Cancer Therapeutics201281
16Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation StatusCancer Research201979
17Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2Oncogene201975
18ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment inEGFR-Mutated Non–Small Cell Lung CancerClinical Cancer Research202075
19Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIMClinical Cancer Research201874
20Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung CancerClinical Cancer Research201769
21Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancerNature Communications202069
22Ligand‐triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligandsCancer Science201264
23KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 familyCell Cycle201363
24Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumabNature Communications201557
25Surfactant Protein A Suppresses Lung Cancer Progression by Regulating the Polarization of Tumor-Associated MacrophagesAmerican Journal of Pathology201356
26Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung CancerAmerican Journal of Pathology201255
27Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine NetworkAmerican Journal of Pathology201154
28Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to boneCancer and Metastasis Reviews200747
29Adverse events of endoscopic ultrasound‐guided fine‐needle aspiration for histologic diagnosis in Japanese tertiary centers: Multicenter retrospective studyDigestive Endoscopy202145
30Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR InhibitorsPLoS ONE201341
31Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugsScientific Reports201540
32Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung CancerJournal of Thoracic Oncology201237
33Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patientsCancer Science201537
34Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS MutationsMolecular Cancer Therapeutics201837
35Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and AngiogenesisJournal of Thoracic Oncology201234
36Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR MutationJournal of Thoracic Oncology201434
37mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGFPLoS ONE201332
38In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4‐ALK lung cancer cell lineCancer Science201532
39Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistanceCancer Science201932
40A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancerLung Cancer202132
41Genetically engineered humanized anti‐ganglioside GM2 antibody against multiple organ metastasis produced by GM2‐expressing small‐cell lung cancer cellsCancer Science201131
42Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancerCancer Science202031
43Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expressionOncogene201630
44Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal CancerJCO Precision Oncology202229
45The novel phosphoinositide 3‐kinase–mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factorInternational Journal of Cancer201328
46Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitorsCancer Science201728
47Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancersOncogene201828
48Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor modelsCancer Immunology, Immunotherapy202128
49Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric CancerClinical Cancer Research202127
50A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung AdenocarcinomaCancer Research201726